ARWRArrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the companys investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity and metabolic dysfunction-associated steatohepatitis...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented new positive clinical data for plozasiran supporting its use in patients with moderate-to-severe renal impairment or moderate hepatic impairment without the need for dose adjustment, and a case report suggesting that preconception...

Wall Street's Cardiac Bet: Where Diagnostics Meet the Money Wall Street's Cardiac Bet: Where Diagnostics Meet the Money PR Newswire VANCOUVER, BC, May 12, 2026 ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.USANewsGroup.com News CommentaryVANCOUVER, BC, May 12, 2026 /PRNewswire/ --Cardiovascular...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026. The Company is hosting a conference call today, May 7, 2026...

SRPT beats Q1 earnings and revenue estimates despite a sharp Elevidys sales drop, while maintaining its 2026 product revenue outlook.

Strs Ohio grew its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 205.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 52-Week High - Should You Buy...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for ARO-PNPLA3, Arrowheads clinical stage RNA...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: BofA Securities 2026 Healthcare Conference May 12-14, 2026 Type...